Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Enrolling By Invitation
18-99 years
All
Phase
2
1 Location
Brief description of study
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Advanced Solid Tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female , Age 18 or older, Confirmed advanced or metastatic solid tumors who have disease progression after treatment with standard therapies
Updated on
01 Aug 2024.
Study ID: 851366
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
